Citation, DOI, disclosures and article data
Citation:
Woolley M, Bell D, Knipe H, F-18 DOPA. Reference article, Radiopaedia.org (Accessed on 07 May 2024) https://doi.org/10.53347/rID-88500
F-18 DOPA (3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine) is a PET radiotracer primarily used in the evaluation of neuropsychiatric diseases, movement disorders, and brain malignancies 1.
Production
L-DOPA is the non-proteinogenic amino acid precursor to dopamine, with F-18 DOPA usually being synthesized by a nucleophilic substitution reaction.
Clinical uses
F-18 DOPA has mainly been used in the assessment of Parkinson disease 2, schizophrenia and gliomas 4. It is also used for pheochromocytoma, extra-adrenal abdominal paraganglioma and congenital hyperinsulinemia 3,5,6.
-
1. Pretze M, Wängler C, Wängler B. 6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses. (2014) BioMed research international. 2014: 674063. doi:10.1155/2014/674063 - Pubmed
-
2. Ibrahim N, Kusmirek J, Struck AF, Floberg JM, Perlman SB, Gallagher C, Hall LT. The sensitivity and specificity of F-DOPA PET in a movement disorder clinic. (2016) American journal of nuclear medicine and molecular imaging. 6 (1): 102-9. Pubmed
-
3. Cristina Nanni, Stefano Fanti, Domenico Rubello. 18F-DOPA PET and PET/CT. (2007) Journal of Nuclear Medicine. 48 (10): 1577. doi:10.2967/jnumed.107.041947 - Pubmed
-
4. Somme F, Bender L, Namer I, Noël G, Bund C. Usefulness of 18F-FDOPA PET for the Management of Primary Brain Tumors: A Systematic Review of the Literature. Cancer Imaging. 2020;20(1):70. doi:10.1186/s40644-020-00348-5 - Pubmed
-
5. Iversen P, Kramer S, Ebbehoj A et al. [18F]FDOPA PET/CT is Superior to [68Ga]DOTATOC PET/CT in Diagnostic Imaging of Pheochromocytoma. EJNMMI Res. 2023;13(1):108. doi:10.1186/s13550-023-01056-4 - Pubmed
-
6. States L, Davis J, Hamel S, Becker S, Zhuang H. J Nucl Med. 2021;62(Suppl 2):51S-6S. doi:10.2967/jnumed.120.246033 - Pubmed
Promoted articles (advertising)